EDGAR·FLOW

Most material SEC filings — November 5, 2026

50 filings analyzed. Top movers: MidCap Financial Investment Corp, Karyopharm Therapeutics Inc., Distribution Solutions Group, Inc., Lantheus Holdings, Inc., Processa Pharmaceuticals, Inc..
8-K MidCap Financial Investment Corp
On October 27, 2026, Ares Capital Corporation (ARCC) announced agreement to acquire MidCap Financial Investment Corp (MFIC) for $10.88 per share in stock-and-cash transaction: $9.67 in ARCC stock plus $1.21 cash. Q3 2026 results show NAV declined 3.8% to $12.86/share (from $13.37), net investment income fell to $0.34/share (from $0.40), and portfolio suffered net realized/unrealized losses of $44.0M, partially offset by $27.6M net investment income.
— Neutral · significance 92 · 8-K Agent
8-K Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. filed an 8-K on November 5, 2026 reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing indicates the company has received notification regarding failure to meet continued listing standards, though specific details of which listing rule was breached, cure periods, or remediation steps are not provided in the document header or summary. This represents a critical threat to the company's public market status.
▼ Likely negative · significance 92 · 8-K Agent
8-K Distribution Solutions Group, Inc.
On July 15, 2026, Distribution Solutions Group entered into a merger agreement with Eclipse entities controlled by LKCM Headwater Investments and CEO J. Bryan King (who collectively own ~79% of DSG). The $35.00 per share all-cash purchase price represents an 81% premium to the March 13, 2026 closing price of $19.31, and a $5.50 increase from LKCM's initial March 14 proposal of $29.50. The deal requires stockholder approval (excluding LKCM votes), HSR clearance (which was obtained August 20, 2026), and customary closing conditions. A special committee of disinterested directors unanimously approved the transaction. Q3 2026 results show revenue of $573.6M (+10.7% YoY), adjusted EBITDA of $56.8M (9.9% margin), and net income of $8.9M. The company will become private upon closing.
— Neutral · significance 92 · 8-K Agent
8-K Lantheus Holdings, Inc.
On August 3, 2026, Lantheus entered into a definitive merger agreement with Curium US Holdings LLC. Curium will acquire all outstanding shares at $102.50 per share in cash, plus contingent value rights (CVRs) of up to $12.00 per share tied to product milestones through 2030, for total consideration up to $114.50 per share and ~$8.0 billion enterprise value. The transaction is expected to create a combined radiopharmaceutical diagnostics and therapeutics company serving 70+ countries; the Board unanimously approved the deal.
— Neutral · significance 92 · 8-K Agent
8-K Processa Pharmaceuticals, Inc.
In July 2026, Processa acquired Vidya Therapeutics and completed a concurrent private placement raising approximately $200M (net proceeds ~$183.3M) from institutional healthcare investors. The transaction funds operations into H2 2029 and refocuses the company on immunological/inflammatory diseases, with lead program VT-7208 (BTK inhibitor) advancing into Phase 2 trials for food allergy, chronic spontaneous urticaria, and relapsing MS. As-converted share count increases to ~309.3M (from ~2.8M common currently outstanding), requiring stockholder approval to convert ~306.5M Series A preferred shares to common.
▲ Likely positive · significance 92 · 8-K Agent
8-K Caribou Biosciences, Inc.
On October 6, 2026, Caribou's Board approved a restructuring and announced exploration of strategic alternatives (merger, acquisition, or dissolution) after deciding to discontinue clinical trials for its two lead programs—vispa-cel and CB-011—and implement substantial workforce reductions. The decision follows challenging financing conditions for allogeneic CAR-T therapies. Q3 2026 showed cash/equivalents of $94.8M (down 34% from $142.8M at year-end 2025) and net loss of $26.6M ($0.25/share), with licensing revenue declining to $1.6M from $2.2M year-over-year.
▼ Likely negative · significance 92 · 8-K Agent
8-K MERCER INTERNATIONAL INC.
On November 2, 2026, Mercer secured restructuring support agreements from holders of >87% of senior notes ($1.275B principal) and majority shareholders. The deal exchanges ~$1.1B senior notes for equity, eliminates ~$96M annual cash interest, and provides $400M fully backstopped new senior secured notes via rights offering. Implementation via prepackaged Chapter 11 for parent and non-operating Texas subsidiary; operations continue unaffected. Q3 2026 Operating EBITDA improved to -$2.9M (vs. -$28.1M YoY) on $13M Peace River government grants and $76M cumulative cost savings; total liquidity ~$143.5M.
▲ Likely positive · significance 92 · 8-K Agent
8-K CVD EQUIPMENT CORP
CVD Equipment (market cap ~$14.6M) discontinued pursuit of new system orders for its primary CVD business, reduced workforce accordingly, and engaged CBRE to sell owned real estate in Central Islip and Saugerties, NY. Q3 2026 revenue fell 72.1% to $1.6M; continuing operations lost $2.1M ($0.30/share) vs. $0.1M profit in Q3 2025. Nine-month net income of $9.4M reflects $14.1M gain from SDC divestiture in Q2; cash increased to $23.5M with zero debt.
▼ Likely negative · significance 89 · 8-K Agent
8-K Korsana Biosciences, Inc.
Korsana completed a merger with Cyclerion Therapeutics in September 2026 concurrent with a $380 million private placement, resulting in cash and equivalents of $456.2 million as of Q3 2026—sufficient to fund operations into 2029. The company strengthened leadership (new CMO, CTO, audit chair) and advanced lead program KRSA-028 with Phase 1 healthy volunteer data expected mid-2027 and proof-of-concept data in Alzheimer's patients by year-end 2027 or Q1 2028. Q3 R&D expenses were $42.1 million; net loss was $46.4 million on 55.1 million shares outstanding.
▲ Likely positive · significance 88 · 8-K Agent
8-K iSpecimen Inc.
iSpecimen completed acquisition of two AI products from Foldlab AI Ltd. on November 2, 2026: a Disease-Associated Protein Discovery AI Agent and Disease Trend Prediction/Monitoring AI Model. Total consideration: $750,000 cash at closing, up to $1.25M in two $625K milestone payments, and $2.5M in common stock (2,907,977 shares at VWAP, issued November 5, 2026). Stock subject to 5-year lock-up, no-leak-out, and voting restrictions; Foldlab retains all economic rights during restriction period.
▲ Likely positive · significance 88 · 8-K Agent
8-K BHAV Acquisition Corp
BHAV Acquisition Corp (a $101.9M SPAC) announced a definitive merger with Nemi Corp, valuing Nemi at $400M pre-money (40M shares at $10/share). The transaction will provide ~$142.5M cash at closing from BHAV's $100M trust account plus a $50M PIPE at $10/share. Nemi, an India-based manufacturing company with $3.7M quarterly operating revenue (annualized ~$14.7M), operates 300K+ sq ft, serves 50+ customers, and has $14M in open purchase orders and $100M in non-binding LOIs through 2028. Closing is expected Q1 2027, subject to shareholder and regulatory approval.
▲ Likely positive · significance 82 · 8-K Agent
8-K Change Agents Corporation.
Change Agents Corporation executed a promissory note with Harllon Holdings LLC dated November 4, 2026, borrowing $250,000 principal with $75,000 original issue discount (total cash repayment $325,000 due January 1, 2027). In addition to cash repayment, the company must issue 50,000 restricted common shares to the lender, subject to shareholder approval. The note permits prepayment at $312,000 by December 1, 2026, with full cash obligations retained even if prepaid.
▼ Likely negative · significance 82 · 8-K Agent
8-K TENAX THERAPEUTICS, INC.
Tenax's Phase 3 LEVEL trial of oral levosimendan (TNX-103) for PH-HFpEF failed its primary endpoint (6-minute walk distance improvement in overall population) but showed post-hoc benefits in sicker subgroups: 26.3-meter 6MWD improvement (p=0.0112), 49% NT-proBNP reduction (p<0.0001), and 3.5 mmHg RVSP reduction (p=0.0045) in prespecified analyses. Company paused LEVEL-2 enrollment to implement protocol amendment enriching for symptomatic patients and secured FDA Type C meeting. Cash position: $113.7M (9/30/26), runway through 2028; Q3 2026 net loss $16.7M; common shares outstanding increased to 45.5M from 9.3M at year-end 2025.
▼ Likely negative · significance 78 · 8-K Agent
8-K InMed Pharmaceuticals Inc.
InMed Pharmaceuticals shareholders approved on November 4, 2026: (1) corporate name change to Mentari Therapeutics, Inc.; (2) a 10:1 share consolidation reducing outstanding shares from 5,493,735 to ~549,374; (3) a merger with Mentari Therapeutics (Delaware) whereby InMed shareholders will receive issuance of >20% new common shares plus contingent value rights (CVRs) tied to future milestone events; and (4) redomestication from British Columbia to Nevada. Voting showed strong shareholder support (88–97% approval across major proposals). The merger is pending satisfaction of closing conditions.
— Neutral · significance 78 · 8-K Agent
8-K IMAX CORP
IMAX reported record Q3 2026 results: revenue of $175.0M (+64% YoY), net income of $117.1M with 67% margin, diluted EPS of $1.96 (+430% YoY), and adjusted EBITDA of $121M at 69% margin. Content Solutions revenue surged 110% to $94M driven by Christopher Nolan's 'The Odyssey' ($550M box office, 30% of film's global total). Global quarterly box office reached record $712M (+90% YoY). System backlog stands at 409 units (65% new locations); 100+ signings YTD. Operating cash flow: $122M YTD (+25% YoY). Liquidity: $641M available.
▲ Likely positive · significance 78 · 8-K Agent
8-K HCW Biologics Inc.
HCW Biologics closed $10.0M debt financing on November 4, 2026, with Streeterville Capital, LLC as sole investor. Structure: $3.24M A-1 Note (8% interest, 24-month maturity, $240K OID) + $7.0M secured B Note (5% interest, 24-month maturity, held in deposit account). Net cash to company: $2.97M at closing plus $7.0M held in escrow; company may exchange B Note for additional A Notes as it repays. Maxim Group LLC received $210K placement fee plus $30K reimbursement.
▲ Likely positive · significance 78 · 8-K Agent
8-K MetaVia Inc.
MetaVia announced interim Phase 1 Part 3B results for DA-1726 (a GLP-1/glucagon dual agonist) showing 68% placebo-adjusted liver-fat reduction (MRI-PDFF), 13.5% placebo-adjusted weight loss, and –0.24 pp placebo-adjusted HbA1c reduction at Day 109 (16 weeks) in 15 obese adults vs. 4 placebo. All 5 participants with baseline liver steatosis normalized to MRI-PDFF <5%; 83% achieved ≥30% liver-fat reduction. No new GI adverse events after Week 9; zero study discontinuations due to GI events. The company plans a 48-week, non-biopsy Phase 2 study in up to 150 patients with MetALD/ALD, targeted to start H2 2027; full Part 3A/3B data expected Q1 2027.
▲ Likely positive · significance 78 · 8-K Agent
8-K Gyrodyne, LLC
Gyrodyne, a $6.2M market-cap liquidating REIT, is terminating its $24–28.74M B2K Flowerfield development agreement (signed July 2025) and instead pursuing a sale of the same 49 acres to New York State, potentially at lower gross price but higher risk-adjusted value. The company reduced headcount from 4 to 1 employee (saving ~$620k), extended a $4M Cortlandt Manor mortgage at 7.28% fixed, and revised Q2 2026 net asset estimates downward from $12.30 to $10.75 per share (~$3.4M aggregate decline) due to lower State sale valuation and anticipated B2K termination costs—yet management deems this strategically preferable given B2K transaction delays and uncertainty. Liquidation timeline remains December 31, 2028.
▼ Likely negative · significance 78 · 8-K Agent
10-Q PERMA FIX ENVIRONMENTAL SERVICES INC
PermaFix Environmental Services signed Master Indefinite Delivery/Indefinite Quantity Subcontract No. 96093-000-00 effective August 11, 2026, with Hanford Tank Waste Operations Closure LLC (H2C) for treatment and disposal of mixed low-level waste. Contract value: $4.367 billion cumulative across all task orders. Work scope: grouting and disposal of pretreated liquid waste (PTW), minimum 400 gallons, maximum 50,000,000 gallons. Ordering period: January 1, 2027 – December 31, 2041 (15 years). Fixed price-per-gallon unit pricing; payment within 30 days of invoice. Individual task orders capped at 3,000,000 gallons each.
▲ Likely positive · significance 78 · Periodic Agent
8-K Definitive Healthcare Corp.
Q3 2026 revenue declined 9% YoY to $54.7M (vs. $60.0M in Q3 2025); net loss improved to $(5.4)M (10% of revenue) from $(17.8)M (30% of revenue) YoY. On September 2, 2026, Advent International submitted a non-binding indication of interest to acquire all outstanding Class A shares and LLC interests not already owned by Advent or founder Jason Krantz. The company suspended financial guidance and cancelled its earnings call due to this development. Adjusted EBITDA was $15.7M (29% margin) vs. $18.9M (32% margin) YoY.
— Neutral · significance 78 · 8-K Agent
8-K Organogenesis Holdings Inc.
Organogenesis reported Q3 2026 net revenue of $45.5M (down $105.0M or 70% from Q3 2025's $150.5M), driven by a 73% decline in Advanced Wound Care revenue ($38.2M vs. $141.5M). The company swung to a net loss of $29.6M (vs. $21.6M profit in Q3 2025). Nine-month 2026 results show net loss of $179.1M (vs. $6.7M loss in nine months 2025). Cash declined to $26.9M (Sept 30, 2026) from $94.3M (Dec 31, 2025). Full-year 2026 guidance: $179.4M–$200.0M revenue (65–68% decline vs. 2025's $564.2M). The company cites a 'market reset' in Advanced Wound Care but claims sequential improvement and market share gains.
▼ Likely negative · significance 78 · 8-K Agent
10-Q Alector, Inc.
Alector granted Genentech exclusive worldwide rights to develop and commercialize AL050, an engineered glucocerebrosidase enzyme replacement therapy for Parkinson's disease and neurodegeneration. Alector receives $100 million upfront payment, up to $1.17 billion in development/regulatory/commercial milestone payments, and tiered royalties on net sales. Genentech assumes all development, manufacturing, and commercialization responsibility; Alector retains ownership of its proprietary Alector Brain Carrier platform for use in its own pipeline.
▲ Likely positive · significance 78 · Periodic Agent
8-K Cable One, Inc.
Cable One reported Q3 2026 net loss of $431.8M (vs. $86.5M net income in Q3 2025), driven by $412.1M non-cash asset impairments ($159.0M franchise agreements, $253.1M goodwill) triggered by stock price decline. Revenues fell 11.7% YoY to $332.2M; Adjusted EBITDA declined 20.8% to $159.8M; operating cash flow fell 40.8% to $92.6M. Company faces $3.55B gross debt with $1.25B revolving facility maturing February 2028, $345M convertible notes due March 2028, and $694.3M term loan due May 2028; liquidity stressed by pending MBI acquisition (put option liability $478.9M as of Sept 30). Management states existing liquidity may be insufficient for debt maturities and explicitly flags potential Chapter 11 bankruptcy if refinancing fails.
▼ Likely negative · significance 78 · 8-K Agent
8-K Drilling Tools International Corp
Drilling Tools International Corporation (market cap ~$49.8M) announced acquisition of Saltire Energy for ~$80M cash plus 17.4M DTI shares (valued at 20-day VWAP as of 10/1/26). Saltire has run-rate Adj. EBITDA of $22.5M (45% margin) and ~63,000 tools. Pro forma company projects $205–220M revenue, $58–68M Adj. EBITDA, and 14–17% Adj. FCF margin; leverage expected to fall from ~2.2x at close to ~1.0x within 24 months. Deal expected to close Q1 2027 pending stockholder approval and financing.
▲ Likely positive · significance 78 · 8-K Agent
4 Corebridge Financial, Inc.
10% owner NIPPON LIFE INSURANCE CO (CRBG) bought 356K shares (~$12.9M) on the open market (0.3% of holdings). Open-market insider purchase — historically a bullish signal.
▲ Likely positive · significance 78 · Insider Agent
8-K NEXTERA ENERGY INC
NextEra Energy agreed to acquire Dominion Energy, Inc. (announced May 15, 2026) via merger for estimated consideration of $62.108 billion: $61.748 billion in NEE stock (738 million shares at $83.71/share as of Oct 30, 2026) plus $360 million cash. Each Dominion share converts to 0.8138 NEE shares plus pro-rata share of $360M cash. Deal includes $2.25B+ customer bill credits over 24–48 months and commitments for $10M/year charitable giving (5 years) and $100M workforce development fund. Regulatory approvals from FERC, NRC, state commissions in VA/NC/SC required. Pro forma shows combined entity with $402.1B assets; goodwill of ~$31.6B preliminary.
— Neutral · significance 78 · 8-K Agent
8-K PodcastOne, Inc.
PodcastOne issued guidance for H1 FY2027 (ended Sept 30, 2026): $31.5M total revenue (+76% Adjusted EBITDA YoY to $3.0M), with Q2 at $15.2M revenue and $1.4M Adjusted EBITDA. The Board formed a special committee on October 28 after receiving multiple inbound acquisition inquiries and intends to retain a financial advisor to evaluate strategic alternatives; no transaction is assured. The company also acquired PodcastOne.AI and holds 750,000 hours of content for AI licensing monetization.
— Neutral · significance 78 · 8-K Agent
4 Coursera, Inc.
10% owner Pale Fire Capital SE (COUR) bought 8.4M shares (~$31.5M) on the open market (18% of holdings). Open-market insider purchase — historically a bullish signal.
▲ Likely positive · significance 78 · Insider Agent
4 Lyell Immunopharma, Inc.
10% owner ARCH Venture Fund XIII, L.P. (LYEL) bought 2.3M shares (~$25.0M) on the open market (38% of holdings). Open-market insider purchase — historically a bullish signal.
▲ Likely positive · significance 78 · Insider Agent
4 Lyell Immunopharma, Inc.
10% owner ARCH Venture Partners IX, LLC (LYEL) bought 2.3M shares (~$25.0M) on the open market (38% of holdings). Open-market insider purchase — historically a bullish signal.
▲ Likely positive · significance 78 · Insider Agent
8-K 3D SYSTEMS CORP
3D Systems exchanged $92.03M aggregate principal of 5.875% Convertible Senior Secured Notes due 2030 (all outstanding) for $85M of new 3.30% Convertible Senior Notes due 2031, 13,471,138 shares of common stock, and $20M cash, plus accrued interest. The exchange eliminates all secured debt and releases collateral liens; closing expected November 12, 2026. The new notes convert at ~$3.43/share (30% premium to Nov 4 closing price of $2.64).
▲ Likely positive · significance 72 · 8-K Agent
8-K COGNITION THERAPEUTICS INC
Cognition Therapeutics achieved FDA alignment on primary/secondary endpoints for a Phase 3 registrational trial of zervimesine (CT1812) in dementia with Lewy bodies (DLB) and received a patent on a novel crystalline form expiring 2045. Q3 2026 net loss was $4.1M ($0.04/share) on R&D spending of $5.1M; the company holds $31.5M cash plus $18.2M in obligated NIH grant funds, estimated sufficient through Q4 2027. Phase 2 START study results in Alzheimer's disease expected H2 2027.
▲ Likely positive · significance 72 · 8-K Agent
8-K Oscar Health, Inc.
Oscar Health reported Q3 2026 net income of $167.3M ($0.49 diluted EPS) vs. $137.5M loss year-ago, driven by improved MLR (84.0% vs. 88.5%), disciplined pricing, and $250M favorable risk adjustment benefit. The company raised full-year 2026 earnings from operations guidance to $850M–$950M (from $600M–$800M), revenue to $19.0B–$19.3B (from $18.7B–$19.0B), and lowered MLR guidance to 80.5%–81.5%. Membership grew to 2.69M from 2.11M year-ago; nine-month net income was $1.21B vs. $90.5M loss.
▲ Likely positive · significance 72 · 8-K Agent
8-K KIMBERLY CLARK CORP
On November 2, 2026, Kimberly-Clark completed its acquisition of Kenvue (spinoff of J&J's consumer health business). Q3 2026 net sales were $4.1B (down 0.4% reported; organic sales down 1.3% due to ~270bps China social media disruption headwind and North America inventory movements). Adjusted operating profit declined 0.9% YoY to $677M; adjusted EPS from continuing operations rose 17.2% to $1.70 (aided by lower interest expense and tax rate), but adjusted EPS attributable to KMB fell 6.6% to $1.70 due to discontinued operations. Company reaffirmed 2026 guidance: organic sales ~100bps below category growth (~1.7%); adjusted operating profit growth mid-single digits; adjusted EPS from continuing operations growth high single digits on constant-currency basis.
— Neutral · significance 72 · 8-K Agent
8-K Real REMAX Group Inc.
On August 24, 2026, Real Brokerage Inc. completed its acquisition of RE/MAX Holdings, Inc., creating Real REMAX Group Inc. (NASDAQ: REAX). Q3 2026 revenue was $727.9M (+28% YoY), though GAAP net loss was $67.2M ($2.25/diluted share) due to $52.3M acquisition costs and $26.4M stock-based severance. Adjusted EBITDA was $33.8M (+66% YoY). The company achieved $40M annualized cost savings within two months and provided 2027 guidance of $175-190M Adjusted EBITDA. The term loan was $525M outstanding at quarter-end after a $25M voluntary repayment. Combined platform now spans ~185,000 agents across 120+ countries.
▲ Likely positive · significance 72 · 8-K Agent
8-K PRECISION BIOSCIENCES INC
Precision BioSciences announced Phase 1 ELIMINATE-B data for PBGENE-HBV (hepatitis B gene therapy) showing 100% pgRNA loss to undetectable at 0.4 mg/kg in 6 evaluable patients, including breakthrough efficacy in a hard-to-treat HBeAg-positive patient (pgRNA declined from 5,750 to undetectable). Liver biopsies confirmed cccDNA elimination (1–1.5-log reductions). Safety was favorable across 59 administrations in 25 patients with no dose-limiting toxicities at 0.4 mg/kg; company is initiating global Phase 2 ELIMINATE-B2 in Q1 2027 evaluating monotherapy and combination with antisense oligonucleotide (bepirovirsen). Additionally, PBGENE-DMD (Duchenne muscular dystrophy program) received independent Data Safety Monitoring Board clearance to continue dosing after first patient completed 8-week safety observation with no serious adverse events.
▲ Likely positive · significance 72 · 8-K Agent
8-K Unity Software Inc.
Unity reported Q3 2026 revenue of $622.1M (+32% YoY), with GAAP net income of $121.6M ($0.25 diluted EPS) versus loss of $126.8M in Q3 2025. Strategic revenue grew 59% to $596.6M, driven by Vector Ads Network (+126% YoY). Adjusted EBITDA reached $257M (41% margin). Q4 guidance: Strategic revenue $683–691M (+65–67% YoY), Adjusted EBITDA $290–295M (+132–136% YoY). Cash increased $587M to $2.65B. Sold Supersonic publishing business on August 4, 2026 for $37.2M.
▲ Likely positive · significance 72 · 8-K Agent
8-K Amylyx Pharmaceuticals, Inc.
Amylyx announced positive Phase 3 LUCIDITY trial results for avexitide in post-bariatric hypoglycemia, showing 55% reduction in hypoglycemic events vs. placebo (p=0.000003) with all secondary endpoints met. The company completed an upsized public offering generating net proceeds of $544.6 million, increasing cash position from $250.8M (June 30, 2026) to $768.1M (September 30, 2026). NDA submission remains on track for end of 2026; commercial team buildout underway for potential 2027 launch. Q3 2026 net loss was $45.5M ($0.38/share) on R&D expenses of $28.4M and SG&A of $21.3M.
▲ Likely positive · significance 72 · 8-K Agent
8-K Monte Rosa Therapeutics, Inc.
Monte Rosa announced positive GFORCE-1 Phase 1 results for MRT-8102 showing 80–90% NEK7 degradation and reduction in inflammatory markers comparable to healthy volunteers across all three doses, with safety profile similar to placebo. Novartis triggered two milestone payments totaling $87.5M ($50M for Sjögren's disease Phase 2 initiation, $37.5M for psoriatic arthritis Phase 2 initiation). Cash position stands at $582.6M as of September 30, 2026, expected to support operations into 2029.
▲ Likely positive · significance 72 · 8-K Agent
8-K NEXSTAR MEDIA GROUP, INC.
Nexstar Media Group, a $4.9B public company, reported Q3 2026 net revenue of $2.133 billion (78% YoY increase), with net income of $250 million, Adjusted EBITDA of $756 million, and Adjusted Free Cash Flow of $443 million. The TEGNA acquisition contributed approximately $765 million of incremental revenue ($352M distribution, $405M advertising). Year-to-date through November 5, 2026, the company repaid $1.3 billion of debt, reduced leverage to 4.04x (from higher post-acquisition debt), and paid $171 million in dividends. However, a preliminary injunction has impaired TEGNA synergy realization, with trial scheduled for July 6, 2027.
▲ Likely positive · significance 72 · 8-K Agent
8-K BlackSky Technology Inc.
BlackSky delivered Q3 2026 record revenue of $42.8M (vs. $19.6M prior year), with space-based intelligence & AI services revenue of $32.7M. Net income was $18.5M and adjusted EBITDA $12.8M (29.9% margin). The company raised full-year 2026 revenue guidance to $140–150M (from prior guidance) and adjusted EBITDA to $18–24M, maintaining capex guidance of $50–60M. Key wins include a $1B France-UAE satellite constellation contract, seven-figure U.S. government and international defense contracts, and a pilot with SkyFi.
▲ Likely positive · significance 72 · 8-K Agent
10-Q Amylyx Pharmaceuticals, Inc.
Amylyx signed two manufacturing and supply agreements: (1) Bachem Americas for an unspecified active pharmaceutical ingredient with a June 2025 LOI providing guaranteed manufacturing slots and capacity commitment (details redacted); (2) PolyPeptide Group AG for Avexitide with an 8-year initial term, minimum annual quantities (redacted), tiered pricing from USD [***] per unit, and non-refundable pre-payments of USD 30 million capacity reservation plus Post-PPQ pre-payment (redacted). Both agreements govern long-term commercial supply with detailed quality, delivery, and termination provisions.
▲ Likely positive · significance 72 · Periodic Agent
8-K Core Scientific, Inc./tx
Core Scientific reported Q3 2026 colocation revenue of $215.4M (up 58% sequentially from $136.7M in Q2), driven by delivery of 485 MW of billing capacity as of September 30, 2026. The company recognized $1.2B net income (primarily from non-cash warrant fair-value gains), with Adjusted EBITDA of $133.6M (57% margin, up from 25% in Q2). CoreWeave contract nearing full completion (~590 MW total, ~$485 MW billing); AMD partnership generating $24B+ in contracted power across multiple sites with initial deliveries expected 1H 2027. Total assets $5.9B; long-term debt $4.3B; stockholders' deficit improved to $(1.1B) from $(2.4B) in Q2.
▲ Likely positive · significance 72 · 8-K Agent
8-K IRONWOOD PHARMACEUTICALS INC
Ironwood raised full-year 2026 U.S. LINZESS net sales guidance from $1.15–$1.20B to $1.20–$1.25B (35%+ YoY growth), total revenue from $460–$485M to $485–$510M, and adjusted EBITDA from $310M to >$350M. Q3 2026: LINZESS U.S. net sales $325M (3.2% YoY), total revenue $133M, GAAP net income $60M, adjusted EBITDA $98M. Year-to-date 2026 U.S. LINZESS sales of $880M already exceed full 2025 total.
▲ Likely positive · significance 72 · 8-K Agent
8-K IOVANCE BIOTHERAPEUTICS, INC.
Iovance reported Q3 2026 product revenue of $122M (vs. $67.5M in Q3 2025, +80% YoY), with U.S. Amtagvi revenue at $102M (+77% YoY). Gross margin expanded to ~60% from 56% in Q2 2026. The company reaffirmed full-year 2026 guidance of $410–420M total revenue. Cash position stands at ~$382M as of September 30, 2026, expected to fund operations into 2029. Key pipeline milestones include 24.6% ORR in 69 mNSCLC patients (IOV-LUN-202), 59.1% ORR in biomarker-selected mNSCLC (POSITILITY trial initiated), and 55.6% ORR in UPS/DDLPS (SARATOGA registrational trial ongoing).
▲ Likely positive · significance 72 · 8-K Agent
8-K TripAdvisor, Inc.
TripAdvisor reported Q3 2026 revenue of $436.4M (down 11% YoY) and a $316.9M GAAP net loss, driven primarily by a non-cash goodwill impairment charge of $369.5M in the Hotels and Other segment. On November 1, 2026, the company completed the sale of TheFork to American Express for approximately $741M net cash proceeds. The company also initiated a restructuring on November 4, 2026 expected to generate $40M in annualized savings with restructuring costs of $15-20M.
▼ Likely negative · significance 72 · 8-K Agent
8-K Zenas BioPharma, Inc.
Zenas reported Q3 2026 results with $647.1M in cash (2.5x company market cap), $10M revenue from Bristol-Myers Squibb milestone, and net loss of $108.9M. Key catalysts: FDA assigned PDUFA target date of May 27, 2027 for obexelimab BLA in IgG4-RD; EMA validated MAA submission; Phase 2 SunStone SLE trial topline results expected Q4 2026; ZB021 Phase 1 data expected Q4 2026. R&D expenses doubled YoY to $58.5M; G&A nearly doubled to $27.4M; $27.5M in milestone payments (InnoCare $25M, Xencor $2.5M).
▲ Likely positive · significance 72 · 8-K Agent
8-K Climb Bio, Inc.
Climb Bio, a clinical-stage biotech with market cap ~$44.8M, reported Q3 2026 cash position of $227.6M (51% of market value) with runway into H2 2028. Key developments: CLYM116 Phase 1 in healthy volunteers showed 90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks, supporting every-12-week dosing; NAVIGATE-2 Phase 2 in IgA nephropathy initiated with initial data expected H1 2027. Budoprutug Phase 2 in primary membranous nephropathy (PrisMN) showed 200 mg dose achieved B-cell depletion, PLA2R antibody reduction, and immunologic remission at 12 weeks; Phase 1b in SLE (17 patients) demonstrated dose-dependent B-cell depletion and favorable safety; additional ITP Phase 1b data expected December 2026. Q3 R&D expenses $11.0M vs $9.1M prior year; net loss $14.6M vs $12.9M prior year.
▲ Likely positive · significance 72 · 8-K Agent
8-K TripAdvisor, Inc.
Matthew Goldberg, President and CEO, agreed to depart by February 16, 2027, remaining through that date for orderly transition. He receives $675k salary severance (9 months), $675k bonus severance (0.75× target), 18 months COBRA subsidy, 50% acceleration of 222,416 RSUs vesting within 18 months, and 50% of 44,410 PSUs with completed performance period. Separately, CFO Michael Noonan resigns effective December 31, 2026; Kristen Dalton becomes interim CFO January 1, 2027. Board engaged search firm for successor CEO.
▼ Likely negative · significance 72 · 8-K Agent
8-K Envoy Medical, Inc.
Envoy Medical announced its investigational Acclaim cochlear implant trial surpassed the six-month follow-up visit for all 56 patients and submitted the second of four planned PMA modules to the FDA post-quarter end. First 10 participants showed 12-month CNC word recognition improvement from 15.2% baseline to 53.2%, a 38 percentage-point gain. Company reported Q3 2026 net loss of $5.2M ($0.50/share) on $66K revenue, with cash of $14.6M and total assets of $19.2M as of September 30, 2026.
▲ Likely positive · significance 72 · 8-K Agent
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.